<DOC>
	<DOCNO>NCT00044044</DOCNO>
	<brief_summary>The purpose study evaluate efficacy drug SM-13496 compare placebo haloperidol patient schizophrenia .</brief_summary>
	<brief_title>A Comparison Study Drug With Placebo Haloperidol Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Lurasidone Hydrochloride</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>Inclusion criterion : The patient primary diagnosis schizophrenia The patient hospitalize acute relapse schizophrenia within 3 week screen The patient duration illness least one year . The patient BPRS score least 42 baseline score least 4 two item positive symptom subcluster PANSS The patient able remain antipsychotic medication 4 day washout period Exclusion criterion : The patient psychiatric hospitalization current hospitalization within 1 month prior screen . The patient consider treatment resistantSubstance abuseProlactin level &gt; 200 ng/mL baseline Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Latuda</keyword>
	<keyword>Lurasidone</keyword>
</DOC>